Bioethics (BOTH) 10-Q 20 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 20, 2024
Details
Registrant CIK	0000894560
Fiscal Year End	--12-31
Registrant Name	BIOETHICS, LTD.
SEC Form	10-Q
Period End date	Mar. 31, 2024
Tax Identification Number (TIN)	87-0485312
Number of common stock shares outstanding		1,135,194
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	true
Small Business	true
Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Securities Act File Number	33-55254-41
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1661 Lakeview Circle
Entity Address, City or Town	Ogden
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84403
City Area Code	801
Local Phone Number	399-3632
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 93	$ 138
Total Current Assets	93	138
TOTAL ASSETS	93	138
CURRENT LIABILITIES
Accounts payable	142,225	122,400
Accounts payable - related party	16,000	14,500
Accrued interest - related parties	105,667	98,406
Accrued interest	103,535	98,363
Convertible notes payable	35,000	35,000
Notes payable	160,000	160,000
Notes payable - related parties	253,584	247,734
Total Current Liabilities	816,011	776,403
TOTAL LIABILITIES	816,011	776,403
STOCKHOLDERS' DEFICIT
Preferred stock, $0.01 par value; 25,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized, 1,135,194 shares issued and outstanding	1,135	1,135
Additional paid-in capital	500,479	500,479
Accumulated deficit	(1,317,532)	(1,277,879)
Total Stockholders' Deficit	(815,918)	(776,265)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 93	$ 138

Condensed Balance Sheets - Pare

Condensed Balance Sheets - Parenthetical - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Condensed Balance Sheets
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	25,000,000	25,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	1,135,194	1,135,194
Common Stock, Shares, Outstanding	1,135,194	1,135,194

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Statements of Operations
NET REVENUES	$ 0	$ 0
OPERATING EXPENSES
General and administrative	27,221	12,027
Total Operating Expenses	27,221	12,027
LOSS FROM OPERATIONS	(27,221)	(12,027)
OTHER INCOME (EXPENSES)
Interest expense	(12,432)	(11,609)
Total Other Income (Expenses)	(12,432)	(11,609)
NET LOSS BEFORE INCOME TAXES	(39,653)	(23,636)
PROVISION FOR INCOME TAXES	0	0
NET LOSS	$ (39,653)	$ (23,636)
BASIC AND DILUTED LOSS PER SHARE	$ (0.03)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	1,135,194	1,135,194

Condensed Statements of Stockho

Condensed Statements of Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Equity, Attributable to Parent, Beginning Balance at Dec. 31, 2022	$ 1,135	$ 500,479	$ (1,180,730)	$ (679,116)
Shares, Outstanding, Beginning Balance at Dec. 31, 2022	1,135,914
NET LOSS	$ 0	0	(23,636)	(23,636)
Equity, Attributable to Parent, Ending Balance at Mar. 31, 2023	$ 1,135	500,479	(1,204,366)	(702,752)
Shares, Outstanding, Ending Balance at Mar. 31, 2023	1,135,914
Equity, Attributable to Parent, Beginning Balance at Dec. 31, 2023	$ 1,135	500,479	(1,277,879)	(776,265)
Shares, Outstanding, Beginning Balance at Dec. 31, 2023	1,135,914
NET LOSS	$ 0	0	(39,653)	(39,653)
Equity, Attributable to Parent, Ending Balance at Mar. 31, 2024	$ 1,135	$ 500,479	$ (1,317,532)	$ (815,918)
Shares, Outstanding, Ending Balance at Mar. 31, 2024	1,135,914

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		404 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
NET LOSS	$ (39,653)	$ (23,636)	$ 1,317,532
Adjustments to reconcile net loss to net cash
Accounts payable	19,825	7,482
Accounts payable - related party	1,500	1,500
Accrued interest - related parties	7,261	6,481
Accrued interest	5,172	5,128
Net Cash Used by Operating Activities	(5,895)	(3,045)
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes payable - related parties	5,850	3,000
Net Cash Provided by Financing Activities	5,850	3,000
DECREASE IN CASH AND CASH EQUIVALENTS	(45)	(45)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	138	295
CASH AND CASH EQUIVALENTS AT END OF PERIOD	93	250	$ 93
SUPPLEMENTAL DISCLOSURES
Cash paid for interest	0	0
Cash paid for income taxes	$ 0	$ 0

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - Bioethics, Ltd. (“the Company”) was organized under the laws of the State of Nevada on July 26, 1990. The Company was organized to provide a vehicle for participating in potentially profitable business ventures which may become available through the personal contacts of and at the complete discretion of the Company’s officers and directors. The Company has not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors. The accompanying financial statements are condensed and have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows for the three months ended March 31, 2024 and 2023 have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2023 audited financial statements. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the operating results for the full year.

NOTE 2 - RELATED PARTY TRANSACT

NOTE 2 - RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 2 - RELATED PARTY TRANSACTIONS	NOTE 2 - RELATED PARTY TRANSACTIONS Management Compensation - During the three months ended March 31, 2024 and 2023, the Company did not pay any compensation to its officers and directors. Beginning August 2017, the Company entered into an oral agreement to pay the Company’s President $500 per month as payment for use of his personal residence as the Company’s office and mailing address. The Company has recorded rent expense of $1,500 during each of the three months ended March 31, 2024 and 2023, which is included in the general and administrative expenses on the statements of operations, of which $16,000 and $14,500 remains payable at March 31, 2024 and December 31, 2023, respectively. On March 8, 2018, the Company entered into a promissory note with a newly-affiliated party in the amount of $43,250. The note is payable on demand and carries interest at 10% per annum. Interest expense for the three months ended March 31, 2024 and 2023 was $1,075 and $1,066, respectively, resulting in accrued interest of $26,231 and $25,156 at March 31, 2024 and December 31, 2023, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $43,250. On December 12, 2017, the Company entered into a promissory note with its President in the amount of $107,000. On various dates from the origin of the note through December 31, 2023, the officer advanced the Company an additional $118,170, and the Company made payments of $20,686, resulting in the total note principal balance of $204,484 at December 31, 2023. During the three months ended March 31, 2024 and 2023, the Company received an additional $5,850 and $3,000, respectively, and did not make any repayments of the principal balance resulting in the total note principal balance of $210,334 at March 31, 2024. The cumulative note balance is uncollateralized, due on demand, and carries interest at 12% per annum. Interest expense on the note for the three months ended March 31, 2024 and 2023 was $6,186 and $5,414, respectively, of which the Company repaid $-0- during the three months ended March 31, 2024, resulting in accrued interest totaling $79,436 and $73,250 at March 31, 2024 and December 31, 2023, respectively.

NOTE 6 - NOTES PAYABLE

NOTE 6 - NOTES PAYABLE	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 6 - NOTES PAYABLE	NOTE 3 - NOTES PAYABLE On June 14, 2016, the Company issued a promissory note in the principal amount of $35,000 to an unaffiliated lender. The Note is due on demand at any time after its original maturity date of June 14, 2017, and carries an interest rate of 8% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $696 and $690, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $21,838 and $21,142, respectively. Principal balance due on the note at March 31, 2024 and December 31, 2023 was $35,000. On August 15, 2018, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note was due on November 15, 2018, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $6,006 and $5,707, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000. On November 15, 2018, the Company issued a promissory note in the principal amount of $20,000 to an unaffiliated lender. The Note was due on February 15, 2019, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $597 and $592, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $12,012 and $11,415, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $20,000. On December 31, 2018, the Company issued a promissory note in the principal amount of $30,000 to an unaffiliated lender. The Note was due on December 31, 2019, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $895 and $888, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $18,017 and $17,122, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $30,000. On January 23, 2019, the Company issued a promissory note in the principal amount of $50,000 to an unaffiliated lender. The Note was due on January 23, 2020, is currently in default, and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $1,492 and $1,479, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $30,029 and $28,537, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $50,000. On May 1, 2020, the Company issued a promissory note in the principal amount of $5,000 to an unaffiliated lender. The Note was due on May 1, 2021 and is now due on demand and carries an interest rate of 12% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $149 and $148, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $2,340 and $2,191, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $5,000. On April 18, 2022, the Company issued a promissory note in the principal amount of $10,000 to an unaffiliated lender. The Note is due on April 18, 2023 and carries an interest rate of 8% per annum. Interest expense for the three months ended March 31, 2024 and 2023 totaled $199 and $197, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $1,532 and $1,363, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000.

NOTE 4 - CONVERTIBLE NOTE PAYAB

NOTE 4 - CONVERTIBLE NOTE PAYABLE	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 4 - CONVERTIBLE NOTE PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE On December 18, 2019, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 18, 2020, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $4,000, which was amortized over the life of the promissory note. At March 31, 2024 and December 31, 2023, the unamortized debt discount was $-0-, and the net convertible note balance was $10,000. The amortization of debt discount was $-0- during the three months ended March 31, 2024 and March 31, 2023. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $3,529 and $3,231, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000. On June 9, 2020, the Company issued a convertible promissory note in the original principal amount of $10,000 to a lender. The Note was due on June 9, 2021, is currently in default, and carries an interest rate of 10% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share. The Company recognized a beneficial conversion feature and recorded a debt discount in the amount of $6,200, which was amortized over the life of the promissory note. At March 31, 2024 and December 31, 2023, the unamortized debt discount was $- 0-, and the net convertible note balance was $10,000. The amortization of debt discount was $-0- during the three months ended March 31, 2024 and 2023, respectively. Interest expense for the three months ended March 31, 2024 and 2023 totaled $249 and $247, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $3,810 and $3,562, respectively. Principal balance on the note at March 31, 2024 and December 31, 2023 was $10,000. On August 3, 2020, the Company issued a convertible promissory note in the original principal amount of $15,000 to a lender. The Note was due on August 3, 2021, is currently in default, and carries an interest rate of 8% per annum. The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share. The Company did not recognize a beneficial conversion feature or debt discount as the conversion price was higher than the market price at the time of issuance of the note. Interest expense for the three months ended March 31, 2024 and 2023 totaled $298 and $296, respectively, resulting in accrued interest at March 31, 2024 and December 31, 2023 of $4,392 and $4,093. Principal balance on the note at March 31, 2024 and December 31, 2023 was $15,000.

NOTE 5 - EQUITY TRANSACTIONS

NOTE 5 - EQUITY TRANSACTIONS	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 5 - EQUITY TRANSACTIONS	NOTE 5 – EQUITY TRANSACTIONS The Company is authorized to issue 250,000,000 shares of common stock. There were no equity transactions during the three months ended March 31, 2024 or 2023, resulting in 1,135,194 shares of common stock issued and outstanding at March 31, 2024 and December 31, 2023.

NOTE 6 - GOING CONCERN

NOTE 6 - GOING CONCERN	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 6 - GOING CONCERN	NOTE 6 - GOING CONCERN The accompanying unaudited condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has incurred losses since its inception totaling $1,317,532 and has no on-going operations. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans, additional sales of its common stock, or through a possible business combination. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

NOTE 7 - LOSS PER SHARE

NOTE 7 - LOSS PER SHARE	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 7 - LOSS PER SHARE	NOTE 7 - LOSS PER SHARE The computation of basic loss per share is based on the weighted average number of shares outstanding during each period. The following data show the amounts used in computing loss per share for the three months ended: March 31, 2024 March 31, 2023 Net loss (numerator) $ (39,653) $ (23,636) Weighted average shares outstanding (denominator) 1,135,194 1,135,194 Basic and fully diluted net loss per share amount $ (0.03) $ (0.02) The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents as detailed in the following chart. For the three months ended March 31, 2024 and 2023, the inclusion of these shares on the statements of operations would have resulted in a weighted average shares fully diluted number that was anti-dilutive, and as such they are excluded. The following data show the fully diluted shares for the three months ended March 31, 2024 and 2023: March 31, 2024 2023 Basic weighted average shares outstanding 1,135,194 1,135,194 Convertible debt 15,061 14,694 Total 1,150,255 1,149,888

NOTE 8 - SUBSEQUENT EVENTS

NOTE 8 - SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2024
Notes
NOTE 8 - SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date the financial statements were issued and determined there are no events requiring disclosure.

NOTE 7 - LOSS PER SHARE_ Schedu

NOTE 7 - LOSS PER SHARE: Schedule of earnings per share (Tables)	3 Months Ended
	Mar. 31, 2024
Tables/Schedules
Schedule of earnings per share	March 31, 2024 March 31, 2023 Net loss (numerator) $ (39,653) $ (23,636) Weighted average shares outstanding (denominator) 1,135,194 1,135,194 Basic and fully diluted net loss per share amount $ (0.03) $ (0.02)

NOTE 7 - LOSS PER SHARE_ Sche_2

NOTE 7 - LOSS PER SHARE: Schedule of fully diluted shares (Tables)	3 Months Ended
	Mar. 31, 2024
Tables/Schedules
Schedule of fully diluted shares	March 31, 2024 2023 Basic weighted average shares outstanding 1,135,194 1,135,194 Convertible debt 15,061 14,694 Total 1,150,255 1,149,888

NOTE 2 - RELATED PARTY TRANSA_2

NOTE 2 - RELATED PARTY TRANSACTIONS (Details) - USD ($)		3 Months Ended
	Dec. 31, 2017	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Mar. 08, 2018	Dec. 12, 2017
Interest Expense, Operating and Nonoperating		$ 12,432	$ 11,609
Director 1
Operating Leases, Rent Expense		1,500	1,500
Due to Related Parties, Current		16,000		$ 14,500
Newly Affiliated Party
Due to Related Parties, Current		26,231		25,156
Debt Instrument, Face Amount					$ 43,250
Debt Instrument, Interest Rate, Stated Percentage					10%
Interest Expense, Operating and Nonoperating		1,075	1,066
Long-Term Debt, Gross		43,250		43,250
Sole Officer And Director
Due to Related Parties, Current		$ 210,334		204,484
Debt Instrument, Face Amount						$ 107,000
Debt Instrument, Interest Rate, Stated Percentage		12%
Interest Expense, Operating and Nonoperating		$ 6,186	5,414
Proceeds from Related Party Debt	$ 118,170	5,850	$ 3,000
Repayments of Related Party Debt	$ 20,686
Repayment of Notes Receivable from Related Parties		0
Interest Payable, Current		$ 79,436		$ 73,250

NOTE 6 - NOTES PAYABLE (Details

NOTE 6 - NOTES PAYABLE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Apr. 18, 2022	May 01, 2020	Jan. 23, 2019	Dec. 31, 2018	Nov. 15, 2018	Aug. 15, 2018	Jun. 14, 2016
Interest Expense, Operating and Nonoperating	$ 12,432	$ 11,609
Promissory Note 1
Debt Instrument, Face Amount										$ 35,000
Debt Instrument, Interest Rate, Stated Percentage										8%
Interest Expense, Operating and Nonoperating	696	690
Interest Payable, Current	21,838		$ 21,142
Long-Term Debt, Gross	35,000		35,000
Promissory Note 2
Debt Instrument, Face Amount									$ 10,000
Debt Instrument, Interest Rate, Stated Percentage									12%
Interest Expense, Operating and Nonoperating	298	296
Interest Payable, Current	6,006		5,707
Long-Term Debt, Gross	10,000		10,000
Promissory Note 3
Debt Instrument, Face Amount								$ 20,000
Debt Instrument, Interest Rate, Stated Percentage								12%
Interest Expense, Operating and Nonoperating	597	592
Interest Payable, Current	12,012		11,415
Long-Term Debt, Gross	20,000		20,000
Promissory Note 4
Debt Instrument, Face Amount							$ 30,000
Debt Instrument, Interest Rate, Stated Percentage							12%
Interest Expense, Operating and Nonoperating	895	888
Interest Payable, Current	18,017		17,122
Long-Term Debt, Gross	30,000		30,000
Promissory Note 5
Debt Instrument, Face Amount						$ 50,000
Debt Instrument, Interest Rate, Stated Percentage						12%
Interest Expense, Operating and Nonoperating	1,492	1,479
Interest Payable, Current	30,029		28,537
Long-Term Debt, Gross	50,000		50,000
Promissory Note 6
Debt Instrument, Face Amount					$ 5,000
Debt Instrument, Interest Rate, Stated Percentage					12%
Interest Expense, Operating and Nonoperating	149	148
Interest Payable, Current	2,340		2,191
Long-Term Debt, Gross	5,000		5,000
Promissory Note 7
Debt Instrument, Face Amount				$ 10,000
Debt Instrument, Interest Rate, Stated Percentage				8%
Interest Expense, Operating and Nonoperating	199	$ 197
Interest Payable, Current	1,532		1,363
Long-Term Debt, Gross	$ 10,000		$ 10,000

NOTE 4 - CONVERTIBLE NOTE PAY_2

NOTE 4 - CONVERTIBLE NOTE PAYABLE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Interest Expense, Operating and Nonoperating	$ 12,432	$ 11,609
A Lender
Debt Instrument, Face Amount	$ 10,000
Debt Instrument, Payment Terms	The Note was due on June 18, 2020, is currently in default, and carries an interest rate of 8% per annum
Debt Instrument, Convertible, Terms of Conversion Feature	The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.00 per share
Debt Instrument, Unamortized Discount	$ 4,000
Debt Instrument, Unamortized Discount, Current	0
Amortization of Debt Discount (Premium)	0	0
Interest Expense, Operating and Nonoperating	298	296
Long-Term Debt, Gross	10,000		$ 10,000
A Lender (2)
Debt Instrument, Face Amount	$ 10,000
Debt Instrument, Payment Terms	The Note was due on June 9, 2021, is currently in default, and carries an interest rate of 10% per annum
Debt Instrument, Convertible, Terms of Conversion Feature	The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $2.50 per share
Debt Instrument, Unamortized Discount	$ 6,200
Debt Instrument, Unamortized Discount, Current			0
Amortization of Debt Discount (Premium)	0	0
Interest Expense, Operating and Nonoperating	249	247
Long-Term Debt, Gross	10,000		10,000
Interest Payable, Current	3,810		3,562
A Lender (3)
Debt Instrument, Face Amount	$ 15,000
Debt Instrument, Payment Terms	The Note was due on August 3, 2021, is currently in default, and carries an interest rate of 8% per annum
Debt Instrument, Convertible, Terms of Conversion Feature	The Note is due and payable in full unless converted partially or in its entirety upon the election of the lender into fully paid and non-assessable shares of common stock of the Company at a conversion rate of $7.00 per share
Interest Expense, Operating and Nonoperating	$ 298	$ 296
Long-Term Debt, Gross	15,000		15,000
Interest Payable, Current	$ 4,392		$ 4,093

NOTE 5 - EQUITY TRANSACTIONS (D

NOTE 5 - EQUITY TRANSACTIONS (Details) - shares	Mar. 31, 2024	Dec. 31, 2023
Details
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	1,135,194	1,135,194
Common Stock, Shares, Outstanding	1,135,194	1,135,194

NOTE 6 - GOING CONCERN (Details

NOTE 6 - GOING CONCERN (Details) - USD ($)	3 Months Ended		404 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024
Details
NET LOSS	$ (39,653)	$ (23,636)	$ 1,317,532

NOTE 7 - LOSS PER SHARE_ Sche_3

NOTE 7 - LOSS PER SHARE: Schedule of earnings per share (Details) - USD ($)	3 Months Ended		404 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024
Details
NET LOSS	$ (39,653)	$ (23,636)	$ 1,317,532
Weighted average shares outstanding (denominator)	1,135,194	1,135,194
Basic and fully diluted net loss per share amount	$ (0.03)	$ (0.02)

NOTE 7 - LOSS PER SHARE_ Sche_4

NOTE 7 - LOSS PER SHARE: Schedule of fully diluted shares (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Details
Basic weighted average shares outstanding	1,135,194	1,135,194
Convertible debt	15,061	14,694
Total	1,150,255	1,149,888